癌症相关泪溢:向三级眼整形专科转诊病例的回顾性分析
该单中心回顾性研究分析了2010至2016年间因癌症相关泪溢转诊至眼整形专科的43例患者(70眼),发现头颈部放疗(35%)、口服S-1(33%)和多西他赛(23%)是最常见原因,梗阻部位与治疗效果因病因不同而异,S-1相关泪溢及延迟治疗与疗效不佳相关。
要点
- 头颈部放疗是癌症相关泪溢最常见原因(35%),其次为口服S-1(33%)和多西他赛(23%)。
- 放疗患者梗阻多位于鼻泪管(59%),S-1(94%)和多西他赛(100%)患者梗阻多位于泪点或泪小管。
- S-1组治疗成功率最低为58%(S-1 vs 放疗:p=0.012;S-1 vs 多西他赛:p=0.002)。
核心结论
- 癌症相关泪溢病因多样,梗阻部位和治疗效果因潜在病因不同而异。
- S-1相关泪溢和延迟治疗与不理想的治疗结果相关。
- 鉴于早期干预的重要性,肿瘤科医生应警惕流泪症状,并在早期阶段与眼科医生合作以改善患者生活质量。
研究设计与样本
- 单中心回顾性研究,纳入2010年至2016年间连续转诊至一位眼整形外科医生的癌症相关泪溢患者。
- 共纳入43例患者(70眼)。
- 查阅病历以获取潜在肿瘤疾病、药房记录、放疗记录、泪道系统梗阻部位以及治疗方法和结果。
主要发现
- 泪溢最常见原因为头颈部放疗(35%),其次为口服S-1(33%)和多西他赛(23%)。
- 放疗患者中最常见梗阻部位为鼻泪管(59%),而S-1(94%)或多西他赛(100%)治疗患者中主要累及泪点或泪小管。
- S-1治疗患者显示整个泪小管严重梗阻(11/24,46%),成功率最低为58%(S-1 vs 放疗:p=0.012;S-1 vs 多西他赛:p=0.002)。
- 在S-1组中,首次症状出现后1年内接受治疗的患者症状改善比例(85%)显著高于1年后治疗者(27%)(p=0.011)。
临床怎么用
- 原文结论提出肿瘤科医生应警惕流泪症状,并在早期阶段与眼科医生合作以改善患者生活质量。
- 原文结论指出鉴于早期干预的重要性,但未给出具体干预推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To report the underlying causes and treatment outcome of lacrimal drainage obstruction in patients with cancer-associated epiphora. METHODS: A single-centre retrospective review was performed for consecutive referrals to an oculoplastic surgeon for cancer-associated epiphora between 2010 and 2016. Charts were reviewed for underlying neoplastic conditions, pharmacy records, radiotherapy records, levels of obstruction of the lacrimal drainage apparatus and treatment methods and outcome. RESULTS: Forty-three patients (70 eyes) were included in this study. The most common cause of epiphora was radiotherapy on the head and neck (35%), followed by oral S-1 (33%) and docetaxel (23%). The nasolacrimal duct was the most common obstruction site in patients who underwent radiotherapy (59%), whereas the punctum or canaliculus was mostly affected in patients treated with S-1 (94%) or docetaxel (100%). S-1-treated patients showed severe obstruction of the entire canaliculus (11/24 (46%)) with the lowest success rate at 58% (S-1 vs radiotherapy: p=0.012; S-1 vs docetaxel: p=0.002). Moreover, the patients treated within 1 year after the first symptom showed a significantly higher proportion of symptom improvement (85%) than did those treated after 1 year (27%) in the S-1 group (p=0.011). CONCLUSIONS: Cancer-associated epiphora can have various causes. The level of obstruction and treatment outcome vary according to underlying causes, and S-1-associated epiphora and delayed treatment are related to unsatisfactory results. Given the importance of early intervention, oncologists should be alert to tearing symptoms and cooperate with ophthalmologists in the early stages to improve patients' quality of life.
引用
- Kang S, Seo JW, Sa HS, et al. Cancer-associated epiphora: a retrospective analysis of referrals to a tertiary oculoplastic practice. Br J Ophthalmol. 2017. PMID: 28341695. doi:10.1136/bjophthalmol-2016-309774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。